hydrochlorothiazide has been researched along with Diabetic Angiopathies in 15 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The safety and efficacy of an amlodipine/olmesartan medoxomil (OM)-based titration regimen was assessed in patients with type 2 diabetes mellitus and hypertension." | 9.15 | Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen. ( Littlejohn, T; Neutel, JM; Qian, C; Ram, CV; Sachson, R; Shojaee, A; Stoakes, KA, 2011) |
| "A total of 422 patients with type 2 diabetes who were hypertensive [sitting systolic blood pressure (SBP) > or = 140 mmHg and/or diastolic blood pressure (DBP) > or = 90 mmHg] and microalbuminuric [urinary albumin excretion (UAE) 30-300 mg/day] were eligible for the study." | 6.70 | Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. ( Aznar, J; Llisterri, JL; Lozano, JV; Redon, J, 2001) |
| " In multivariable Cox analyses, adjusting for randomized treatment, age, sex, race, prior anti-hypertensive therapy, baseline uric acid, serum creatinine and glucose entered as standard covariates, and in-treatment non-HDL cholesterol, Cornell product left ventricular hypertrophy, diastolic and systolic pressure, BMI, hydrochlorothiazide and statin use as time-varying covariates, the lowest quartile of in-treatment HDL remained associated with a nearly 9-fold increased risk of new diabetes (hazard ratio 8." | 5.17 | In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study. ( Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Lindholm, LH; Okin, PM; Wiik, BP, 2013) |
| "The safety and efficacy of an amlodipine/olmesartan medoxomil (OM)-based titration regimen was assessed in patients with type 2 diabetes mellitus and hypertension." | 5.15 | Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen. ( Littlejohn, T; Neutel, JM; Qian, C; Ram, CV; Sachson, R; Shojaee, A; Stoakes, KA, 2011) |
| "We conducted a prospective, randomized, open-label, blinded endpoint crossover study comparing the metabolic responses to the addition of either hydrochlorothiazide (HCTZ) or indapamide, in 18 diabetic hypertensive patients receiving ACE inhibitor monotherapy for hypertension." | 5.10 | Comparative metabolic effects of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy. ( Gilbert, RE; Krum, H; Skiba, M, 2003) |
| "5 mg of hydrochlorothiazide, in 90 type 2 diabetic patients with microalbuminuria and blood pressure > 130/85 mmHg, receiving losartan 50 mg as initial treatment during 4 weeks." | 5.10 | Losartan titration versus diuretic combination in type 2 diabetic patients. ( de Pablos-Velasco, PL; Esmatjes, JE; Fernandez-Vega, F; Lopez de la Torre, ML; Pazos Toral, F; Pozuelo, A; Ruilope, LM, 2002) |
| "The effects of long-term treatment with captopril and conventional therapy on albuminuria and metabolic parameters were compared in 74 hypertensive type II diabetics with normal serum creatinine." | 5.07 | Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. ( Lacourcière, Y; Nadeau, A; Poirier, L; Tancrède, G, 1993) |
| " The aim of this study was to compare the effects of an equivalent reduction in blood pressure produced by the angiotensin-converting enzyme (ACE) inhibitor spirapril (SPI) and an antihypertensive triple drug combination of hydralazine, reserpine and hydrochlorothiazide (HRH) on kidney function, proteinuria and renal structure in hypertensive diabetic rats." | 3.70 | Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats. ( Armini, L; Bardelli, M; Calci, M; Campanacci, L; Candido, R; Carretta, R; Fabris, B; Fazio, M; Fischetti, F, 1999) |
| "Treatment with spironolactone improved coronary microvascular function, raising the possibility that MR blockade could have beneficial effects in preventing cardiovascular disease in patients with T2DM." | 2.80 | Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes. ( Adler, GK; Baimas-George, M; Di Carli, MF; Foster, C; Garg, R; Hurwitz, S; Jerosch-Herold, M; Kwong, RY; Rao, AD; Shah, RV, 2015) |
| " After a 4-week wash-out period, 209 patients were randomized to either CC 8 mg or AML 5 mg once daily for a minimum of 1 month, after which, if BP was not normalized, the dosage was doubled, followed by the addition of hydrochlorothiazide 12." | 2.74 | Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study. ( Asmar, R; Baguet, JP; Mallion, JM; Nisse-Durgeat, S; Valensi, P, 2009) |
| "A total of 422 patients with type 2 diabetes who were hypertensive [sitting systolic blood pressure (SBP) > or = 140 mmHg and/or diastolic blood pressure (DBP) > or = 90 mmHg] and microalbuminuric [urinary albumin excretion (UAE) 30-300 mg/day] were eligible for the study." | 2.70 | Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. ( Aznar, J; Llisterri, JL; Lozano, JV; Redon, J, 2001) |
| "Care must be taken in treating hypertension in diabetic patients because the choice of antihypertensive agent may worsen the diabetic state or its complications or cause additional health problems for the patient." | 1.27 | Treatment of hypertension in diabetic men: problems with sexual dysfunction. ( Lipson, LG, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (20.00) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okin, PM | 1 |
| Hille, DA | 1 |
| Wiik, BP | 1 |
| Kjeldsen, SE | 1 |
| Lindholm, LH | 1 |
| Dahlöf, B | 1 |
| Devereux, RB | 1 |
| Garg, R | 1 |
| Rao, AD | 1 |
| Baimas-George, M | 1 |
| Hurwitz, S | 1 |
| Foster, C | 1 |
| Shah, RV | 1 |
| Jerosch-Herold, M | 1 |
| Kwong, RY | 1 |
| Di Carli, MF | 1 |
| Adler, GK | 1 |
| Baguet, JP | 1 |
| Asmar, R | 1 |
| Valensi, P | 1 |
| Nisse-Durgeat, S | 1 |
| Mallion, JM | 1 |
| Ram, CV | 1 |
| Sachson, R | 1 |
| Littlejohn, T | 1 |
| Qian, C | 1 |
| Shojaee, A | 1 |
| Stoakes, KA | 1 |
| Neutel, JM | 1 |
| Krum, H | 1 |
| Skiba, M | 1 |
| Gilbert, RE | 1 |
| SANCHETTI, P | 1 |
| FAVERO, S | 1 |
| Karalliedde, J | 1 |
| Smith, A | 1 |
| DeAngelis, L | 1 |
| Mirenda, V | 1 |
| Kandra, A | 1 |
| Botha, J | 1 |
| Ferber, P | 1 |
| Viberti, G | 1 |
| Lipson, LG | 1 |
| Lacourcière, Y | 1 |
| Nadeau, A | 1 |
| Poirier, L | 1 |
| Tancrède, G | 1 |
| Byington, RP | 1 |
| Furberg, CD | 1 |
| Craven, TE | 1 |
| Pahor, M | 1 |
| Sowers, JR | 1 |
| McFarlane, R | 1 |
| McCredie, RJ | 1 |
| Bonney, MA | 1 |
| Molyneaux, L | 1 |
| Zilkens, R | 1 |
| Celermajer, DS | 1 |
| Yue, DK | 1 |
| Fabris, B | 1 |
| Candido, R | 1 |
| Armini, L | 1 |
| Fischetti, F | 1 |
| Calci, M | 1 |
| Bardelli, M | 1 |
| Fazio, M | 1 |
| Campanacci, L | 1 |
| Carretta, R | 1 |
| Lozano, JV | 1 |
| Llisterri, JL | 1 |
| Aznar, J | 1 |
| Redon, J | 1 |
| de Pablos-Velasco, PL | 1 |
| Pazos Toral, F | 1 |
| Esmatjes, JE | 1 |
| Fernandez-Vega, F | 1 |
| Lopez de la Torre, ML | 1 |
| Pozuelo, A | 1 |
| Ruilope, LM | 1 |
| Siperstein, MD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease[NCT00865124] | 69 participants (Actual) | Interventional | 2008-09-30 | Completed | |||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Coronary flow reserve (CFR), or myocardial perfusion reserve, was assessed via cardiac positron emission tomography (PET). CFR is the ratio of adenosine-stimulated blood flow through myocardium to resting blood flow through myocardium. An improvement in coronary flow reserve is beneficial. (NCT00865124)
Timeframe: Baseline and six months
| Intervention | ratio (Mean) |
|---|---|
| Spironolactone (MR Blockade) | 0.33 |
| Hydrochlorothiazide + Potassium | -0.10 |
| Placebo | 0.02 |
Diastolic function was assessed via tissue doppler imaging (TDI) by echocardiography to determine left ventricular diastolic function before and after 6 months of treatment. (NCT00865124)
Timeframe: Baseline and six months
| Intervention | ratio (Mean) |
|---|---|
| Spironolactone (MR Blockade) | 0.02 |
| Hydrochlorothiazide + Potassium | 0.06 |
| Placebo | 0.64 |
Renal vasculature was assessed by examining renal plasma flow, or para-aminohippurate (PAH) clearance, basally and in response to acute administration (3 nanograms/kg/min for 60 min) of the vasoactive agent, Angiotensin II. (NCT00865124)
Timeframe: Baseline and six months
| Intervention | mL/min/1.73m^2 (Mean) | |||
|---|---|---|---|---|
| Pre-treatment, PAH clearance, baseline | Pre-treatment, PAH clearance, Post-ANGII | 6 months post-treatment, PAH clearance, baseline | 6 months post-treatment, PAH clearance, Post-ANGII | |
| Hydrochlorothiazide + Potassium | 508 | 417 | 500 | 415 |
| Placebo | 518 | 436 | 491 | 427 |
| Spironolactone (MR Blockade) | 527 | 442 | 518 | 423 |
Diastolic function was assessed via tissue doppler imaging (TDI) by echocardiography to determine left ventricular diastolic function before and after 6 months of treatment; and in response to acute administration (3 nanograms/kg/min for 60 min) of the vasoactive agent, Angiotensin II. (NCT00865124)
Timeframe: Baseline and six months
| Intervention | ratio (Mean) | |||
|---|---|---|---|---|
| Pre-treatment, E/e', baseline | Pre-treatment, E/e', Post-ANGII | 6 months post-treatment, E/e', baseline | 6 months post-treatment, E/e', Post-ANGII | |
| Hydrochlorothiazide + Potassium | 6.72 | 7.06 | 7.03 | 5.83 |
| Placebo | 6.55 | 6.70 | 7.35 | 7.48 |
| Spironolactone (MR Blockade) | 6.67 | 7.09 | 6.76 | 6.28 |
11 trials available for hydrochlorothiazide and Diabetic Angiopathies
| Article | Year |
|---|---|
In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study.
Topics: Aged; Antihypertensive Agents; Atenolol; Cholesterol, HDL; Comorbidity; Diabetes Mellitus, Type 2; D | 2013 |
Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Coronary Circulation; Diabetes Mellitus, Type | 2015 |
Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Coronary Circulation; Diabetes Mellitus, Type | 2015 |
Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Coronary Circulation; Diabetes Mellitus, Type | 2015 |
Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Coronary Circulation; Diabetes Mellitus, Type | 2015 |
Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2009 |
Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, | 2011 |
Comparative metabolic effects of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cross-Over Studie | 2003 |
Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; An | 2008 |
Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis.
Topics: Aged; Albuminuria; Blood Pressure; Captopril; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Doub | 1993 |
Isradipine in prediabetic hypertensive subjects.
Topics: Antihypertensive Agents; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Cardiovascular Dis | 1998 |
Angiotensin converting enzyme inhibition and arterial endothelial function in adults with Type 1 diabetes mellitus.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Cross-Over Studies; Diabetes Mellitus, Type 1; Diab | 1999 |
Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics.
Topics: Albuminuria; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, | 2001 |
Losartan titration versus diuretic combination in type 2 diabetic patients.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes Mellit | 2002 |
4 other studies available for hydrochlorothiazide and Diabetic Angiopathies
| Article | Year |
|---|---|
[CLINICAL STUDY OF A NEW COMPLEX HYPOTENSIVE DRUG COMBINATION].
Topics: Antihypertensive Agents; Arteriosclerosis; Carbamates; Cerebrovascular Disorders; Coronary Disease; | 1963 |
Treatment of hypertension in diabetic men: problems with sexual dysfunction.
Topics: Antihypertensive Agents; Blood Pressure; Diabetic Angiopathies; Erectile Dysfunction; Humans; Hydroc | 1984 |
Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Diabetic | 1999 |
Type II diabetes: some problems in diagnosis and treatment.
Topics: Blood Glucose; Chlorpropamide; Confusion; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; | 1985 |